Nintedanib: A Study Drug for COVID-19 Interstitial Lung Disease (ILD)
Nintedanib is a study drug to slow the rate of lung scarring from interstitial lung disease (ILD), a lung injury caused by COVID-19. Scientists and doctors do not know the effectiveness of the treatment. Research is needed to learn if the drug may be approved and used to improve the health of people suffering from ILD.
For more information contact:
Who can participate?
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
- All genders 18+
- In-person at University of Utah
- At least 30 days passed since first symptoms and positive COVID-19 test
- After COVID-19 diagnosis, required supplemental oxygen, noninvasive ventilation such as CPAP or BIPAP, or mechanical ventilation
- Signs of interstitial lung disease
- Active COVID-19 infection
- Active Hepatitis A/B/C
- Pregnant or breastfeeding women
- Pre-existing interstitial lung disease and/or liver disease
- Patients in an intensive care unit (ICU) or in the step-down unit if on invasive or non-invasive mechanical ventilation, ECMO, or high flow nasal cannula oxygen
Will I be paid for my time?